All In Biotech

Drug Trial Radar · NCT03522298

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide

Last checked: Nov 19, 2026Latest source record: Mar 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

May 15, 2018

Primary completion

Mar 30, 2023

Study completion Mar 30, 2023

Sponsor

Lead sponsor
Kazia Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
May 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This protocol has a 2-part design: This phase 2 study is an open-label, multicenter, dose-escalation and expansion study to assess the safety, tolerability, recommended phase 2 dose (RP2D), pharmacokinetics (PK) and clinical activity of paxalisib in patients with newly-diagnosed glioblastoma (GBM) with unmethylated MGMT promoter status as adjuvant therapy following surgical resection and initial chemoradiation with temozolomide (TMZ).

Conditions

  • Glioblastoma, Adult

Interventions

  • Paxalisib (GDC-0084)Drug

    Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1, Days 1-28

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Los Angeles - Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • University of Oklahoma Health Sciences Center (Stephenson Cancer Center)

    Oklahoma City, Oklahoma

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.